Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, SE-751 83 Uppsala, Sweden.
Antaros Medical AB, SE-431 83 Mölndal, Sweden.
Int J Mol Sci. 2021 Jul 8;22(14):7348. doi: 10.3390/ijms22147348.
Pathological fibrosis of the liver is a landmark feature in chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Diagnosis and assessment of progress or treatment efficacy today requires biopsy of the liver, which is a challenge in, e.g., longitudinal interventional studies. Molecular imaging techniques such as positron emission tomography (PET) have the potential to enable minimally invasive assessment of liver fibrosis. This review will summarize and discuss the current status of the development of innovative imaging markers for processes relevant for fibrogenesis in liver, e.g., certain immune cells, activated fibroblasts, and collagen depositions.
肝脏的病理性纤维化是慢性肝病的一个显著特征,包括非酒精性脂肪性肝病 (NAFLD) 和非酒精性脂肪性肝炎 (NASH)。目前,对其进行诊断和评估病情进展或治疗效果需要进行肝脏活检,这在纵向干预性研究中存在一定挑战。例如,正电子发射断层扫描 (PET) 等分子成像技术具有实现肝纤维化微创评估的潜力。本综述将总结和讨论目前与肝纤维化形成相关的创新成像标志物的开发情况,例如某些免疫细胞、活化的成纤维细胞和胶原沉积等。